Viewing Study NCT03370367

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:40 AM
Ignite Modification Date: 2026-05-27 @ 11:05 AM
Study NCT ID: NCT03370367
Status: COMPLETED
Last Update Posted: 2023-06-15
First Post: 2017-12-07
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer
Sponsor: Eastern Cooperative Oncology Group
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Stage I-II Head and Neck Cancer View
Keywords: